

News Releases

All Years

Search

Go

[Advanced Search](#)

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

AUG 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

MAY 12, 2022

Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Show per
page

[«](#) [1](#) [...](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [...](#) [16](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=5&o=40>